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Background: We investigated the use of the gonadotropin-releasing hormone (GnRH) antagonist degarelix in
everyday clinical practice using registry data from uro-oncology practices in Germany.
Methods: Data were analysed retrospectively from the IQUO (Association for uro-oncological quality assurance)
patient registry. Data were prospectively collected from all consecutive PCa patients treated with degarelix
(n = 1010) in 138 uro-oncology practices in Germany between May 2009 and December 2013.
Results: Median overall survival had not yet been reached in the all-patient group or in subgroups who had
or had not received prior hormonal therapy (HT). Cox regression analysis showed that patients who had received prior
HT (n = 542) had a 58 % increased mortality risk (hazard ratio 1.58, 95 % CI 1.20–2.09) versus patients who
had not (n = 468) (p = 0.001). Also, in patients who had received prior luteinizing hormone-releasing hormone
(LHRH) analogue therapy (LHRH agonists or GnRH antagonists), median time to PSA progression was shorter
(209 weeks) than in those who had not received prior LHRH analogues (n = 555; median PSA progression-free
survival not yet reached). Degarelix was generally well tolerated.
Conclusions: Degarelix was effective and well tolerated in everyday clinical practice, confirming observations
from clinical studies. Patients who received prior HT appeared to have a significantly higher mortality risk.
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The gonadotropin-releasing hormone (GnRH) antagon-
ist, degarelix, is an effective and well tolerated treatment
for advanced prostate cancer (PCa) [1–3]. As an antag-
onist, degarelix benefits from a direct mechanism of
action that inhibits GnRH without causing an initial
surge in gonadotropins or consequently testosterone [4].
Degarelix displays similar efficacy to the luteinizing
hormone-releasing hormone (LHRH) agonist, leuprolide,
for testosterone suppression in PCa [1]. However, testos-
terone reduction was more rapid with degarelix and,* Correspondence: goetz.geiges@freenet.de
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or microsurges; in advanced disease, the testosterone
surge associated with LHRH agonists can produce
symptom flare [5]. Degarelix also displayed superior
prostate-specific antigen (PSA) progression-free survival
(PFS) compared with leuprolide [6] and in metastatic
disease was associated with better control of the bone for-
mation marker serum alkaline phosphatase (S-ALP), sug-
gesting that it might offer prolonged control of skeletal
metastases [7].
While degarelix has been well studied in clinical trials,
it is important to examine its efficacy and tolerability in
everyday clinical practice. Clinical trials give important
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population (with few excluded patients), allowing evalu-
ation of care as actually provided [8]. Consequently,
registry data are likely to provide a more representative
indication of the real-world patient experience with
degarelix. Therefore, the current study investigated the
use of degarelix in patients from uro-oncology practices
in Germany by analysing data from the IQUO (Association
for uro-oncological quality assurance) Firmagon® pa-
tient registry.
Methods
Data were analysed retrospectively from the IQUO (As-
sociation for uro-oncological quality assurance) patient
registry records using the QuaSi-URO® documentation
system, a live system based on data from IQUO mem-
bers. Data from the Firmagon® Registry (The Electronic
Therapy Documentation [ETD] Firmagon® – Urology)
were prospectively collected from all consecutive patients
with PCa treated with degarelix in 138 uro-oncology prac-
tices in Germany between 27 May 2009 and 10 December
2013. All patients with PCa receiving degarelix who were
entered into ETD Firmagon® were documented and all
patients with at least one fully documented entry in the
registry were included. The only criterium for inclusion
into the registry was prescription of degarelix, thus every-
day usage should be mirrored by this register. The deci-
sion to treat patients with degarelix was taken by the
treating physician before the decision for inclusion into
the registry.
The underlying data collection for this publication was
performed in accordance with the principles of the Dec-
laration of Helsinki. The data collection did not take
place in a study environment but utilized electronic data
capture according to the documentation system and
documentation guidelines of the IQUO. Within the elec-
tronic data capture there is no personal or patient iden-
tifying information; data were collected anonymously
and pseudonymised. Identification of patients is possible
only by the physician and the documentation staff.
Therefore, according to three independent legal opin-
ions there was no need for ethics committee approval
or a patient consent form.
Study variables
The data repository was reviewed for information on the
following variables: tumour response to degarelix; overall
survival (OS); PSA PFS; percentage change in median
PSA and testosterone over time; percentage of patients
with PSA ≤ 4 ng/ml over time; percentage change in
median S-ALP over time; change in mean prostate
volume. These variables were measured for patient
subgroups as summarized in Table 1. Prior hormonal
therapy (HT) included LHRH agonists, GnRH antagonistsor antiandrogens. Prior LHRH analogue therapy included
LHRH agonists or GnRH antagonists. Recording of the
testosterone, S-ALP and prostate volume at the time of
documentation was optional.
Tumour response (objective progression or stabilization,
complete or partial remission) was assessed using the
Response Evaluation Criteria In Solid Tumors [RECIST]
guidelines [9] and measured at 6-month intervals up to a
total duration of 3 years. Median time to PSA progression
was defined according to Prostate Cancer Clinical Trials
Working Group [PCWG2] criteria: a ≥25 % increase and
an absolute increase of ≥2 ng/ml from the nadir, confirmed
by a second value ≥3 weeks later [10]. At the time of PSA
progression, patients were also required to have testoster-
one levels < 0.5 ng/ml [castration level]. The date of PSA
progression was the date of the first PSA test value.
Percentage change in median PSA, testosterone and
S-ALP, and mean prostate volume were measured
monthly during the first year of treatment and there-
after in 3-monthly intervals for up to 39 months.
Percentage change in median PSA and percentage of
patients with PSA ≤ 4 ng/ml are presented for 3-
month intervals for up to 36 and 24 months, respectively.
Longer term data is not shown due to the smaller patient
numbers towards the end of the evaluation period,
especially in subgroups. Since collection of testoster-
one, ALP and prostate volume data was optional, pa-
tient numbers are smaller and therefore percentage
change in median testosterone is presented for up to
2 years (1 year in metastatic disease subgroup), S-
ALP for up to 1 year and mean prostate volume for
up to 6 months.
The first data point in the registry refers to the
time of the first administration of degarelix (baseline).
In ongoing treatments, the last data point refers to
the time of the last documented administration of a
degarelix dose.
Statistics
Change in PSA, S-ALP, and prostate volume are summa-
rized using descriptive statistics (percentage change, per-
centage change in median, mean). OS and PSA PFS
were analysed using the Kaplan–Meier method. Survival
was calculated from the date of first treatment until the
date of any cause of death.
Results
Patients
A total of 1,010 patients received degarelix and were in-
cluded. Baseline demographic and disease characteristics
of the registry population are summarized in Table 2.
Around two-thirds of patients had localized (n = 469) or
locally advanced (n = 201) disease (340 had metastatic
disease) and almost half had a Gleason score of 8–10.
Table 1 Summary of efficacy evaluations according to patient subgroup
Patient subgroup
Evaluation All patients Patients with
metastatic disease









Overall survival √ √ √ √ √
PSA progression-free survival √ √ √ √
Percentage change in median
PSA
√ √ √ √
Percentage change in median
testosterone
√ √ √ √
Percentage change in median
S-ALP
√ √
Mean prostate volume √
Percentage of patients with
PSA≤ 4 ng/ml
√ √ √
aLHRH agonists, GnRH antagonists or antiandrogens; bLHRH agonists or GnRH antagonists
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dominantly LHRH agonists (53.7 %); of these, 455 had
received prior LHRH analogue therapy (LHRH agonists
or GnRH antagonists). Baseline PSA (median 14.27 ng/ml)
was ≥20 ng/ml in 43.6 % of patients.
At the time of this report, a total of 401, 158 and 44
patients had received degarelix for 12, 24 and 36 months,
respectively; only two patients had received treatment
for 48 months, reflecting entry to the register over time,
at the time of this analysis.
Reasons for discontinuation of degarelix in patients
with documented answers (n = 479) included change
in therapy (30.7 %), patient request/others (22.8 %),
death (14.2 %), PSA progression (14.4 %), clinical pro-
gression (7.5 %), adverse event (6.1 %) or lost to
follow-up (4.4 %).
Tumour response
After 1 year of treatment, among patients with a docu-
mented response (n = 221), 19.9 % (n = 44) had complete
remission, 19.5 % (n = 43) partial remission, 27.6 %
(n = 61) objective stabilization and 21.7 % (n = 48)
objective progression; 11.3 % (n = 25) were not evaluable.
After 24 months (n = 80), these values were 18.8 % (n = 15),
22.5 % (n = 18), 25.0 % (n = 20), 22.5 % (n = 18) and 11.3 %
(n = 9), respectively. After 36 months, (n = 23), these values
were 34.8 % (n = 8), 17.4 % (n = 4), 21.7 % (n = 5), 26.1 %
(n = 6) and 0 % (n = 0), respectively. Patient responses over
time are summarized in Fig. 1.
Overall survival
In total, 212 of 1,010 patients died and 51 were lost
to follow-up. The median OS (all patients) had not
yet been reached; the 75th percentile value (i.e. where
25 % of patients had reached event) was 148.9 weeks.While the median OS had also not yet been reached
in patients with or without prior HT, the 75th per-
centile value was longer for those without prior HT
(176.4 weeks) compared with those with prior HT
(131.7 weeks). A Cox regression analysis showed patients
who received prior HT (n = 542) had a 58 % increased
mortality risk (hazard ratio 1.58, 95 % CI 1.20–2.09)
compared with patients who had not received prior
HT (n = 468) (p = 0.001).
Similarly, median OS had not been reached in patients
with or without prior LHRH analogue therapy (LHRH
agonist/GnRH antagonist), however, the 75th percentile
value was shorter (123.1 weeks) in those who received
prior LHRH analogues compared with those who had
not (167.4 weeks).
PSA PFS
Of the 1,010 patients in this study, 200 (20 %) experi-
enced PSA progression, 137 patients died, 41 were lost
to follow-up and 632 were alive and PSA progression-
free. Median PSA PFS was not yet reached; the 75th
percentile value for PSA PFS was 59.6 weeks.
Of the 340 patients with metastatic disease, 91 (27 %)
experienced PSA progression. Median time to PSA pro-
gression (PSA PFS) was 141.4 weeks (75th percentile
value 32.4 weeks).
In patients who received prior LHRH analogue therapy
(n = 455), median time to PSA progression was shorter
(209 weeks [75th percentile value 30.4 weeks]) than in
those who had not received prior LHRH analogues
(n = 555) where median PSA PFS was not reached
(75th percentile value 88.4 weeks). Also, a greater
proportion of patients who received prior LHRH analogue
therapy (25.05 %; n = 114) experienced PSA progression
compared with those who had not (15.5 %, n = 86).
Table 2 Baseline patient characteristics
Characteristic N = 1,010 (100)
Mean (SD) age,1 years 70.29 (8.55)
Mean (SD) BMI,1 kg/m2 26.88 (3.81)
Median (range) PSA ng/ml 14.27 (0–6131)
Median (range) testosterone ng/ml (n = 266)a 0.52 (0–34.45)
Testosterone categories n, % (n = 266)
<0.1 ng/ml 26 (9.8)
0.1–≤ 0.2 ng/ml 54 (20.3)
0.2–0.5 ng/ml 48 (18.1)
> 0.5 ng/ml 138 (51.9)
Disease stage n (%)
Localizedb 469 (46)
Locally advancedc 201 (20)
Metastaticd 340 (34)





Not classified 19 (2.2)
PSA categories n, %
< 10 ng/ml 438 (43.4)
10– ≤ 20 ng/ml 133 (13.1)
20–50 ng/ml 160 (15.8)




















LHRH agonists 309 (57.0)
Table 2 Baseline patient characteristics (Continued)





Baseline is defined as the beginning of degarelix therapy. aDocumentation of
the testosterone value was optional; bLocalized disease: T1/T2, NX or N0, and
MX or M0; cLocally advanced disease: T3/T4, NX or N0, and MX or M0;
dMetastatic disease: N1 or M1, any T
1Recorded at the time of initial diagnosis of PCa
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Overall, degarelix produced a rapid and profound PSA
reduction, sustained for up to 36 months (Fig. 2a). A
similar PSA profile was observed in patients with base-
line metastatic disease (Fig. 2b). PSA suppression was
greater and more rapid, and maintenance of PSA sup-
pression more effective, in patients who had not received
prior HT compared with those who had received prior
HT (Fig. 2c–d).
Overall, PSA reduction to ≤ 4 ng/ml was achieved in
65 % of patients at 12 months and 71 % of patients at
24 months (Fig. 3a). These values were lower in patients
with metastatic disease (41 % and 63 %, respectively)
and patients with baseline PSA ≥20 ng/ml (41 % and
44 %, respectively); (Fig. 3b–c).
Testosterone
Overall, degarelix produced a rapid and profound reduc-
tion in testosterone (an optional measurement), falling
to 0.19 ng/mL after 1 month (n = 217). Testosterone
suppression <20 ng/mL was sustained for the first
24 months in the all-patient group (median testosterone
0.13 ng/mL at 24 months [n = 18]). Testosterone was
also suppressed in patients with baseline metastatic
disease: median testosterone level was 0.2 ng/mL after
1 month (n = 92) and 0.13 ng/mL at 12 months (n = 20).Fig. 1 Patient response to treatment over time
Fig. 2 Percentage change in median PSA over time in (a) all patients; b patients with metastatic disease at baseline; c patients with prior
hormonal therapy; and (d) patients with no prior hormonal therapy
Geiges et al. BMC Urology  (2015) 15:122 Page 5 of 9S-ALP
Changes in S-ALP (an optional measurement) over
time for patients with metastatic disease (n = 70 at
0 months and n = 11 at 12 months) and those without
prior HT (n = 53 at 0 months and n = 11 at 12 months)
are summarized in Fig. 4. In the metastatic cohort, S-
ALP was suppressed after 6–12 months of treatment.
S-ALP suppression was observed after 1 month in pa-
tients with no prior HT and this was maintained for up
to 12 months.
Prostate volume
Mean prostate volume decreased from 36.83 ml at base-
line (n = 85 patients) to 30.32 ml (n = 25) after 3 months
and to 26.38 ml after 6 months (n = 16).
Tolerability
The most frequent adverse events recorded in patients
included hot flushes (12.9 %), injection site erythema
(8.5 %), fatigue (5.2 %) and pain (4.2 %). Adverse events
experienced by patients at the first and last data points
during degarelix therapy are summarized in Table 3.Apart from a slight increase in the incidence of hot
flushes, there were no significant changes in frequency
of adverse events between the first and last data points.
Discussion
Patient registries offer a unique and powerful tool for
the collection of observational and clinical data, helping
provide a clearer understanding of a therapy's impact on
patients in a real-world context. While patient popula-
tions in clinical trials are tightly controlled, with rigorous
selection criteria, registries generally have much broader
inclusion criteria and fewer exclusion criteria which can
lead to greater generalizability [11].
Degarelix is a GnRH antagonist for the first-line treat-
ment of androgen-dependent advanced PCa. However,
comparison of patient populations in the Firmagon
registry versus clinical trials shows that while degarelix
trials excluded patients with previous hormonal manage-
ment of PCa (except those who underwent localized
therapy of curative intent in which neoadjuvant or adju-
vant HT for ≤ 6 months was accepted) [1, 3, 12, 13], over
half the patients in the current registry had received
Fig. 3 Percentage of patients with PSA≤ 4 ng/ml over time for (a) all patients; b patients with metastatic disease at baseline; and (c) patients
with baseline PSA ≥20 ng/ml
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prior LHRH agonists). It was observed that, in this study
of real-world experience with degarelix therapy, of those
with documented answers, degarelix was discontinued in
30.7 % of patients due to a change in therapy and in
22.8 % as a result of patient request/other reasons com-
pared with 14.4 % of patients discontinuing due to PSA
progression and 7.5 % due to clinical progression. Infor-
mation regarding the reasons for patients changing ther-
apy was not collected in the current analysis; reasons for
changing treatment may possibly include higher expecta-
tions regarding efficacy and/or lowering side effects.
Also, 34 % of the registry population had baseline
metastastic disease compared with around 20 % [1, 12, 13]
to 23 % [3] in clinical trials. Interestingly, in our registry,
46 % of patients who received degarelix had localised dis-
ease and over half had PSA ≤20 ng/mL. In the community
setting, ADT has been used commonly as primary therapy
for localised prostate cancer [14] particularly in the elderly
[15]. However, European Association of Urology guide-
lines consider androgen suppression to be unsuitable asprimary therapy for low-risk prostate cancer and consider
that, in patients with non-metastatic localised disease not
suitable for curative treatment, immediate ADT should be
used only in patients requiring symptom palliation [16].
In the current study, degarelix achieved a complete
response in 20 % of patients after 1 year and 19 % after
2 years; although this value rose to 35 % at 3 years, pa-
tient numbers at this time were small. Partial responses
were noted in 20 %, 22.5 % and 17 % of patients, after 1,
2 and 3 years, respectively. In the degarelix trial of
Ozono et al. [3], the best overall response (complete re-
sponse [3.6 %] + partial response [67.9 %]) was 71.4 % in
the 240/80 mg group.
In our registry study, patients with prior HT appeared
to have a significantly higher mortality risk (hazard ratio
1.58) compared with those who had not received prior
HT. Castration resistance and concomitant progression
is inevitable in these patients and it is not surprising that
prior HT shortens the observed remission time for every
other androgen deprivation therapy, such as degarelix,
that commences thereafter. Also, in the subgroup who
Fig. 4 Percentage change in median serum alkaline phosphatase
over time in (a) patients with metastatic disease at baseline and
(b) patients with no prior hormonal therapy
Table 3 Adverse events at first and last data points during
degeralix therapy
Adverse event n,% First data pointa Last data pointb
Totalc 276 (27.3) 380 (37.6)
Hot flushes 80 (7.9) 130 (12.9)
Erythema at the injection site 61 (6.0) 86 (8.5)
Fatigue 41 (4.1) 53 (5.2)
Pain 29 (2.9) 42 (4.2)
Weight gain 20 (2.0) 20 (2.0)
Back pain 10 (1.0) 18 (1.8)
Hypertension 12 (1.2) 6 (0.59)
Cardiac arrhythmia 3 (0.3) 3 (0.3)
Thromboembolism 0 0
Heart attack 2 (0.2) 1 (0.1)
Arteriosclerosis 0 1 (0.1)
Osteoporosis 0 1 (0.1)
Others 18 (1.8) 19 (1.9)
aAt the time of the first degarelix dose; bat the final degarelix dose;
cpercentages are stated as a percentage of the total patient population
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GnRH antagonist), the 75th percentile value for OS was
shorter than in those not pre-treated with LHRH ana-
logues. Similarly, a higher percentage of patients who
had received prior LHRH analogues experienced PSA
progression compared with those who had not, and me-
dian time to PSA progression was shorter (209 weeks) in
the subgroup who had received prior LHRH analogues
versus those who had not (median PSA PFS not
reached). These results appear to compare favourably
with earlier studies of ADT. One large study of ADT in
previously untreated PCa patients showed a median PFS
of 16.5 months and 13.9 months, with LHRH agonists
with and without antiandrogen, respectively [17]. In
other studies in previously hormone-naïve patients, simi-
lar times to progression have been noted with LHRH
agonists with/without antiandrogens (in the range of 12
to 23 months) [18–22].
Data from clinical studies show that degarelix dis-
played superior PSA PFS compared with leuprolide over
1 year [6], and there was an improvement in PSA PFS in
patients who crossed over from leuprolide to degarelix
in a long-term extension trial [2]. Furthermore, a pooled
analysis also showed improved PSA PFS and longer OS
(likely due to a decreased risk of cardiovascular disease)
with degarelix compared with LHRH agonists [23]. In-
deed, compared to LHRH agonists, GnRH antagonists
appear to halve the number of cardiac events experi-
enced by men with pre-existing cardiovascular disease
during the first year of ADT [24]. Improvements in PSA
PFS are indicative of delayed progression to castration-
resistant disease with degarelix. Interestingly, since over
half of the registry patients had received prior HT, it was
not expected to achieve the same efficacy as in con-
trolled studies which generally excluded patients who
had prior HT. Nevertheless, the current registry data indi-
cate that degarelix provides some benefit in patients who
were pre-treated with HT (e.g. LHRH-agonists), while
most benefit was observed in hormone-naïve patients.
PSA suppression in registry patients with no prior HT
was more rapid and effective than those pre-treated with
HT; moreover, the hormone-naïve cohort showed a PSA
suppression profile similar to that observed with degare-
lix in clinical trials where previous hormonal manage-
ment of PCa was excluded.
In the registry patients, PSA reduction to ≤ 4 ng/ml was
achieved in 65 % of patients at 12 months and 71 % at
24 months. In the pivotal phase III degarelix clinical trial
(CS21), the proportion of patients achieving PSA suppres-
sion < 4 ng/ml was 83 % after 1 year [6]. The difference
most likely reflects the fact that patients in the registry
had a higher risk compared to the registration trial, CS21.
Over time, the proportion of registry patients with meta-
static disease who achieved PSA suppression < 4 ng/ml
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larly, the proportion of patients with metastatic disease
in the CS21 trial achieving PSA suppression < 4 ng/ml
was also lower than the overall study population.
Southwest Oncology Group trial S9346 data showed
that PSA ≤ 4 ng/ml after ADT is a strong predictor of
survival [25]. After controlling for prognostic factors,
patients with PSA ≤ 4 to > 0.2 ng/ml had less than one-
third the risk of death versus those with PSA > 4 ng/ml;
median survival was 13 months for patients with PSA >
4 ng/ml versus 44 months for patients with PSA > 0.2
to ≤ 4 ng/ml.
The registry data also showed that overall, degarelix
produced a rapid and profound testosterone suppression
that was sustained for up to 24 months. Testosterone
was also suppressed in patients with baseline metastatic
disease. Testosterone measurement was optional and so,
over time, patient numbers were small.
S-ALP is a marker of bone formation and baseline levels
are high in metastatic disease, indicative of skeletal metas-
tases [7]. Therefore, we examined the effect of degarelix in
the cohort of patients with metastatic disease and found
that S-ALP was suppressed after 6–12 months with degar-
elix. This compares with S-ALP suppression below base-
line levels in the metastatic cohort after only 2 months of
degarelix therapy in the CS21 trial [7]. A decrease in bone
turnover marker levels may delay progression of bone
metastases and improve survival.
Neo-adjuvant ADT can reduce prostate volume before
radiotherapy. The registry data showed a decrease in
prostate volume of almost 18 % at 3 months (and ~28 %
at 6 months). This is slightly below the reported reduc-
tions (37–42 %) in prostate volume achieved with degar-
elix in clinical studies [26, 27]. As well as facilitating
more effective delivery of radiotherapy, rapid and pro-
nounced reduction of total prostate volume may also
provide additional benefit for patients with obstructive
lower urinary tract symptoms.
Degarelix was well tolerated in registry patients, with
similar adverse event profiles for patients at the first and
last data points. Moreover, the adverse event profile
(based on adverse events at the last data point) was as
expected for this patient population and similar to that
of patients receiving degarelix in the 1-year phase II and
III clinical trials, with the most frequent adverse events
typically comprising injection-site reactions, hot flushes,
and fatigue [1, 12, 13].
Some limitations of registry-based cohort studies may
include limited availability of treatment data and under-
reporting of outcomes if a patient leaves the registry or
is not adequately followed up [11]. In the current regis-
try, over time, patient numbers for some parameters (es-
pecially e.g. testosterone, prostate volume, and S-ALP
where recording was optional) became quite small insome patient subgroups (e.g. metastatic patients) which
may affect the reliability of measurements towards the
end of the observation period in these cases. Missing
data are a common phenomenon in healthcare research
projects; not all data provided are complete due to the
non-interventional nature of this study type. The uncer-
tainty based on this will be relativized by the collection
and generation of more data. Where there is a signifi-
cant quantity of missing data, this may bias or impact
on the study finding. One reason for the reduced num-
ber of patients is that some patients at the time of the
analysis had not yet reached the full follow-up period.Conclusion
This analysis of registry data showed degarelix to be ef-
fective and well tolerated in this real-world setting, con-
firming observations from controlled clinical studies.
PSA-PFS appeared to be more favourable in comparison
to earlier studies with other ADT treatments. Patients
who had received prior HT appeared to have a signifi-
cantly higher mortality risk than those who had not
received prior HT.
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